AstraZeneca says disappointed with FDA Lynparza vote outcome

AstraZeneca said the FDA committee voted 11 to one, with one abstaining, to limit its Lynparza treatment to patients whose tumors have a breast cancer gene, or BRCA, mutation.
Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.